Development of an Oral Form of Azacytidine: <svg style="vertical-align:-0.252pt;width:49.224998px;" id="M1" height="20.612499" version="1.1" viewBox="0 0 49.224998 20.612499" width="49.224998"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,20.6125)">
		<g transform="translate(72,-55.51)">
			<text transform="matrix(1,0,0,-1,-71.95,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟐</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-62.98,63.44)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-58.86,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟑</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-49.89,63.44)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-45.77,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟓</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-36.8,63.22)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

		</g>
	</g>
</svg>Triacetyl-5-Azacytidine

<table>TAC-associated effect on hematological parameters following TAC administration to CD-1 mice. RTC: reticulocyte count, WBC: white blood cell count, NEU: neutrophil count, LYM: lymphocyte count, MNO: monocyte count, EOS: eosinophil count, LUC: large unstained cell count.</table>

Chemotherapy Research and Practice

fig5

Figure 5

Figure 5: Development of an Oral Form of Azacytidine: <svg style="vertical-align:-0.252pt;width:49.224998px;" id="M1" height="20.612499" version="1.1" viewBox="0 0 49.224998 20.612499" width="49.224998"  xmlns="http://www.w3.org/2000/svg">
	<g transform="matrix(1.25,0,0,-1.25,0,20.6125)">
		<g transform="translate(72,-55.51)">
			<text transform="matrix(1,0,0,-1,-71.95,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟐</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-62.98,63.44)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-58.86,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟑</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-49.89,63.44)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-45.77,55.81)">
				<tspan style="font-size: 17.93px; " x="0" y="0">𝟓</tspan>
			</text>

			<text transform="matrix(1,0,0,-1,-36.8,63.22)">
				<tspan style="font-size: 12.55px; " x="0" y="0">′</tspan>
			</text>

		</g>
	</g>
</svg>Triacetyl-5-Azacytidine 

Figure 5 | Development of an Oral Form of Azacytidine: 
	
		
			
				𝟐
			

			
				′
			

			
				𝟑
			

			
				′
			

			
				𝟓
			

			
				′
			

		
	
Triacetyl-5-Azacytidine 

Chemotherapy Research and Practice

Development of an Oral Form of Azacytidine: 𝟐 ′ 𝟑 ′ 𝟓 ′ Triacetyl-5-Azacytidine

Figure 5

Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine